Business Context and Reporting Period
TransCode Therapeutics, Inc. filed a Form 8-K on November 9, 2023, reporting an event occurring November 7, 2023. The filing concerns Nasdaq continued-listing compliance for the company’s common stock, which trades under the symbol RNAZ on The Nasdaq Capital Market.
Key Financial and Listing Metrics
- Nasdaq notified the company that its common stock had failed to maintain the $1.00 minimum closing bid price for 30 consecutive business days, from September 26 through November 6, 2023.
- The filing does not provide revenue, profit, cash flow, margin, debt, cash, or other operating financial metrics.
- Nasdaq also previously determined that the company did not meet the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1).
Material Changes Versus the Prior Comparable Period
The material development is the new minimum-bid-price deficiency notification. The company’s existing stockholders’ equity deficiency and related Nasdaq proceedings remain outstanding.
- The company received an initial 180-calendar-day period, ending May 6, 2024, to regain compliance with the minimum bid price requirement.
- Compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days during the applicable period.
- Separately, Nasdaq’s Hearings Panel granted an exception from the stockholders’ equity requirement through January 22, 2024, subject to specified reporting and compliance conditions.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The company must provide Nasdaq with a detailed update regarding the stockholders’ equity requirement by November 14, 2023, and an update demonstrating long-term compliance by January 22, 2024.
- If the company does not regain minimum-bid-price compliance by May 6, 2024, it may qualify for an additional 180-day period if it meets applicable market value and other initial listing standards and provides the required notice to Nasdaq.
- The company may consider measures to regain compliance, including a reverse stock split, but no such action was announced in the filing.
- If compliance is not achieved, Nasdaq may issue a delisting determination. The company could appeal to a Nasdaq Hearings Panel, although there is no assurance that an appeal would succeed.
- Nasdaq reserved the right to reconsider the stockholders’ equity exception if circumstances arise that make continued listing inadvisable or unwarranted.
- Management states that there is no assurance the company will regain either listing deficiency, obtain an additional compliance period, satisfy the Panel’s conditions, or maintain continued Nasdaq listing.
Important Facts for Investors to Verify
- Whether the company restored a closing bid price of at least $1.00 for 10 consecutive business days by the applicable deadline.
- Whether the company met the stockholders’ equity requirement or obtained any subsequent Nasdaq relief by January 22, 2024.
- Any reverse stock split, equity financing, or other capital-raising action intended to address the deficiencies.
- Any Nasdaq delisting determination, hearing, appeal, or change in the company’s listing status.
- The company’s latest reported cash position, operating loss, cash burn, and capital requirements, which are not provided in this Form 8-K.